Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SIGA, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Tecovirimat (ST-246) FDA approved Jul 2018 · Tpoxx |
Smallpox | Phase 4 · NCT04485039 | Completed |
| Tecovirimat Monohydrate | Smallpox | Phase 4 · NCT04392739 | Completed |
| MVA-BN Smallpox Vaccine | Smallpox | Phase 2 · NCT04957485 | Active not recruiting |
| TPOXX IV (Tecovirimat Injection, 10 mg/m | Orthopox Virus Infection | N/A · NCT05380752 | No longer available |
Also used in these trials (approved or third-party drugs, not SIGA's own candidates): Calcium Acetate, Lanthanum Carbonate, Sevelamer Carbonate, Sucroferric Oxyhydroxide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SIGA holds $117.6M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SIGA files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SIGA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →